The research aims to evaluate the safety and effectiveness of self-mixed 0.125% morphine gel for pain control in cancer lesions.
Conducted a small study evaluating morphine gel's efficacy and safety.
Focused on topical application for cancer-related pain.
Self-mixed 0.125% morphine gel demonstrated effectiveness in pain relief.
The gel was noted to be safe and affordable.
Resumen
This small study suggests that self-mixed 0.125% morphine gel is a safe, effective, and affordable option to control pain in cancer lesions. Larger studies are needed to confirm these results.